ACOX1 Antibody - #DF12046

(7)   (10)  
Product: ACOX1 Antibody
Catalog: DF12046
Description: Rabbit polyclonal antibody to ACOX1
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 50 kDa; 74kD(Calculated).
Uniprot: Q15067
RRID: AB_2844851

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(92%)
Clonality:
Polyclonal
Specificity:
ACOX1 Antibody detects endogenous levels of total ACOX1.
RRID:
AB_2844851
Cite Format: Affinity Biosciences Cat# DF12046, RRID:AB_2844851.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ACOX; ACOX1; ACOX1_HUMAN; Acyl CoA oxidase 1 palmitoyl; Acyl CoA oxidase straight chain; AOX; EC 1.3.3.6; PALMCOX; Palmitoyl CoA oxidase; Palmitoyl-CoA oxidase; Peroxisomal acyl coenzyme A oxidase 1; Peroxisomal acyl-coenzyme A oxidase 1; Peroxisomal fatty acyl CoA oxidase; SCOX; Straight chain acyl CoA oxidase; Straight-chain acyl-CoA oxidase;

Immunogens

Immunogen:
Uniprot:

Q15067(ACOX1_HUMAN) >>Visit HPA database.

Gene(ID):
ACOX1(51)
Expression:
Q15067 ACOX1_HUMAN:

Widely expressed with highest levels of isoform 1 and isoform 2 detected in testis. Isoform 1 is expressed at higher levels than isoform 2 in liver and kidney while isoform 2 levels are higher in brain, lung, muscle, white adipose tissue and testis. Levels are almost equal in heart.

Sequence:
MNPDLRRERDSASFNPELLTHILDGSPEKTRRRREIENMILNDPDFQHEDLNFLTRSQRYEVAVRKSAIMVKKMREFGIADPDEIMWFKKLHLVNFVEPVGLNYSMFIPTLLNQGTTAQKEKWLLSSKGLQIIGTYAQTEMGHGTHLRGLETTATYDPETQEFILNSPTVTSIKWWPGGLGKTSNHAIVLAQLITKGKCYGLHAFIVPIREIGTHKPLPGITVGDIGPKFGYDEIDNGYLKMDNHRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMVFVRSFLVGEAARALSKACTIAIRYSAVRHQSEIKPGEPEPQILDFQTQQYKLFPLLATAYAFQFVGAYMKETYHRINEGIGQGDLSELPELHALTAGLKAFTSWTANTGIEACRMACGGHGYSHCSGLPNIYVNFTPSCTFEGENTVMMLQTARFLMKSYDQVHSGKLVCGMVSYLNDLPSQRIQPQQVAVWPTMVDINSPESLTEAYKLRAARLVEIAAKNLQKEVIHRKSKEVAWNLTSVDLVRASEAHCHYVVVKLFSEKLLKIQDKAIQAVLRSLCLLYSLYGISQNAGDFLQGSIMTEPQITQVNQRVKELLTLIRSDAVALVDAFDFQDVTLGSVLGRYDGNVYENLFEWAKNSPLNKAEVHESYKHLKSLQSKL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Rabbit
100
Dog
92
Chicken
78
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q15067 As Substrate

Site PTM Type Enzyme
T20 Phosphorylation
S26 Phosphorylation
K29 Ubiquitination
K89 Acetylation
K122 Ubiquitination
S127 Phosphorylation
S167 Phosphorylation
K198 Acetylation
Y200 Phosphorylation
K216 Ubiquitination
Y232 Phosphorylation
K255 Acetylation
Y256 Phosphorylation
K260 Ubiquitination
K267 Acetylation
Y275 Phosphorylation
K295 Ubiquitination
K437 Acetylation
Y487 Phosphorylation
K500 Acetylation
K504 Acetylation
K512 Acetylation
Y629 Phosphorylation
S639 Phosphorylation
K643 Acetylation
K643 Ubiquitination
S649 Phosphorylation
K651 Acetylation

Research Backgrounds

Function:

Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. Isoform 1 shows highest activity against medium-chain fatty acyl-CoAs and activity decreases with increasing chain length. Isoform 2 is active against a much broader range of substrates and shows activity towards very long-chain acyl-CoAs. Isoform 2 is twice as active as isoform 1 against 16-hydroxy-palmitoyl-CoA and is 25% more active against 1,16-hexadecanodioyl-CoA.

Subcellular Location:

Peroxisome.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed with highest levels of isoform 1 and isoform 2 detected in testis. Isoform 1 is expressed at higher levels than isoform 2 in liver and kidney while isoform 2 levels are higher in brain, lung, muscle, white adipose tissue and testis. Levels are almost equal in heart.

Subunit Structure:

Homodimer (By similarity). Interacts with LONP2.

Family&Domains:

Belongs to the acyl-CoA oxidase family.

Research Fields

· Cellular Processes > Transport and catabolism > Peroxisome.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Metabolism > Lipid metabolism > Fatty acid degradation.

· Metabolism > Lipid metabolism > alpha-Linolenic acid metabolism.

· Metabolism > Lipid metabolism > Biosynthesis of unsaturated fatty acids.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

References

1). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=7.5]

Application: WB    Species: Human    Sample: L02 cell

Fig. 6. β-PAE promotes the expression of hepatic lipid oxidation-related proteins and genes in HFD-fed rats. (A–G) Western blot analysis on the expression of SIRT1, PGC-1α, PPARα, FGF21, CPT-1a and ACOX1; (H–K) The mRNA expression of SIRT1, PPARα, CPT-1a and ACOX1. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.
2). An effective sodium-dependent glucose transporter 2 inhibition, canagliflozin, prevents development of hypertensive heart failure in dahl salt-sensitive rats. Frontiers in Pharmacology, 2022 (PubMed: 35370704) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 6 Effect of CANA on the cardiac protein expression. (A) Heat map of individual genes within selected pathways, colored by the log2fold change; (B) Selected genes (Acadsb, Ndufb4, Pdk4, Acox1, Bdh1, and Ehhadh) were validated by Western blotting; (C,D) Quantitative evaluation of the protein expression of selected genes (Acadsb, Ndufb4, Pdk4, Acox1, Bdh1, and Ehhadh). * p < 0.05, ** p < 0.01 vs. NSD. # p < 0.05 vs. HSD.
3). Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. International Journal of Molecular Sciences, 2021 (PubMed: 34576229) [IF=5.6]
4). Targeted changes in blood lipids improves fibrosis in renal allografts. Lipids in health and disease, 2023 (PubMed: 38049842) [IF=4.5]

Application: IHC    Species: Rat    Sample: kidneys

Fig. 2 Fenofibrate treatment attenuated fibrosis in a rat model of renal transplantation. A Schematic view of the treatment of fenofibrate in a rat model of renal transplantation. B Gross morphology of bilateral kidneys from rat underwent kidney transplantation (KT). C IF detected the expression of ACOX1 and α-SMA in transplanted kidney of rats, cell nuclei were strained in blue, renal tubular epithelial cells were stained green, ACOX1 was stained violet, and α-SMA was stained red. Scale bar: 50 μm. D HE, Masson, and Sirius Red staining in transplanted kidney from rat models with or without fenofibrate treatment. Scale bar: 50 μm. E Relative fibrosis level compared fenofibrate treatment group with control group. Significance was determined by Student’s t test.

Application: IF/ICC    Species: Rat    Sample: kidneys

Fig. 2 Fenofibrate treatment attenuated fibrosis in a rat model of renal transplantation. A Schematic view of the treatment of fenofibrate in a rat model of renal transplantation. B Gross morphology of bilateral kidneys from rat underwent kidney transplantation (KT). C IF detected the expression of ACOX1 and α-SMA in transplanted kidney of rats, cell nuclei were strained in blue, renal tubular epithelial cells were stained green, ACOX1 was stained violet, and α-SMA was stained red. Scale bar: 50 μm. D HE, Masson, and Sirius Red staining in transplanted kidney from rat models with or without fenofibrate treatment. Scale bar: 50 μm. E Relative fibrosis level compared fenofibrate treatment group with control group. Significance was determined by Student’s t test.
5). Combined effects of ambient particulate matter exposure and a high-fat diet on oxidative stress and steatohepatitis in mice. PLoS One, 2019 (PubMed: 30921449) [IF=3.7]

Application: WB    Species: mouse    Sample: liver

Fig 3. |Ambient PM exposure leads to hepatic steatosis by impairing hepatic lipid metabolism. (A) Oil Red O staining observation of liver (×200, scale bars = 100 μm). (B) H&E staining observation of liver (×200, scale bars = 50 μm). (C) The volume density of quantitation of hepatic steatosis (n = 5). (D) The genes expression involved in fatty acid β-oxidation in liver (n = 5). (E) The mRNA expression of genes involved in lipogenesis and FXR in liver (n = 5). (F) Bands of PPARα,PPARγ, ACOX1, FAS, SREBP-1c, SCD1.
6). MiR-103-3p promotes hepatic steatosis to aggravate nonalcoholic fatty liver disease by targeting of ACOX1. MOLECULAR BIOLOGY REPORTS, 2022 (PubMed: 35606603) [IF=2.8]

Application: WB    Species: Mice    Sample: liver tissue

Fig. 3 Antagomir-103-3p alleviated the damage to mice with NAFLD. Mice with NAFLD were fed an HFD for 8 weeks, and Antagomir-NC or Antagomir-103-3p was used for tail vein injection once a week for 2 weeks. A MiR-103-3p expression in mouse liver tissues was examined by qRT-PCR. B Oil Red O staining detected lipid droplet accumulation in mouse liver tissues, and HE staining detected liver tissue lesions in mice. C The TG, ALT, AST and H2O2 contents in mouse serum were examined, while ROS generation and ATP content were examined in mouse tissues. D The protein and mRNA levels of ACOX1, FASN and ACSL1 were examined by western blotting and qRT-PCR, respectively. *P < 0.05 compared with the control group; #P < 0.05 compared with the NAFLD+Antagomir-NC group
7). Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. Oxidative Medicine and Cellular Longevity, 2022 (PubMed: 35592528)

Application: WB    Species: Mouse    Sample: HepG2 cells

Figure 2 Amelioration of lipid accumulation in PA-induced HepG2 cells by FV. (a) Oil red O was used to measure the level of lipid accumulation (magnification 100x, scale bar = 250 μm). (b) The oil red O-positive area was analyzed and quantified. (c–j) The relative mRNA expression levels of FABP1, SCD1, CD36, HMGCR, ACACA, CCL5, IL-1β, and TNF-α were determined by qRT-PCR. (k) The proinflammatory factor protein levels of IL-1β, IL-6, and TNF-α. (l) The protein levels related to lipid metabolism of SREBP-1, ACOX1, CD36, CPT1α, and HMGCR were analyzed by western blotting, and the relative ratios were calculated and expressed as the mean ± SD; n = 3. #P < 0.05 means that the difference between the NC group and the PA group is significant. ∗P < 0.05 means that the difference between the PA group and the FV (30 mg/mL) group or the FV (15 mg/mL) group is significant.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.